RMTINasdaqPharmaceutical PreparationsFiscal year ends December 31
ROCKWELL MEDICAL, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$7.49+0.06 (+0.81%)
Close on Oct 19, 2026
- Market cap
- $29.65M
- P/E (TTM)
- –
- Dividend yield
- –
Rockwell Medical statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Rockwell Medical | Industry median |
|---|---|---|
| Market Cap | $30.19M | $166.30M |
| Enterprise Value | $14.39M | $87.12M |
| PS Ratio | 0.44 | 3.60 |
| PB Ratio | 0.86 | 2.03 |
| P/TBV Ratio | 1.22 | 2.31 |
| P/FCF Ratio | 19.60 | 17.44 |
| P/OCF Ratio | 10.42 | 13.32 |
Enterprise value
| Measure | Rockwell Medical | Industry median |
|---|---|---|
| EV / Sales | 0.21 | 2.43 |
| EV / FCF | 9.34 | 20.97 |
Income (trailing twelve months)
| Measure | Rockwell Medical | Industry median |
|---|---|---|
| Revenue | $69.39M | $57.94M |
| Gross Profit | $12.29M | $90.47M |
| Operating Income | -$4.52M | -$21.49M |
| Net Income | -$5.08M | -$22.46M |
| EBITDA | -$2.43M | -$17.14M |
| EPS (Diluted) | -$1.38 | -$0.83 |
Margins
| Measure | Rockwell Medical | Industry median |
|---|---|---|
| Gross Margin | 17.7% | 52.3% |
| Operating Margin | -6.52% | -44.5% |
| Profit Margin | -7.33% | -39.2% |
| EBITDA Margin | -3.50% | -31.3% |
| FCF Margin | 2.22% | -8.85% |
Returns
| Measure | Rockwell Medical | Industry median |
|---|---|---|
| Return on Equity (ROE) | -15.5% | -53.2% |
| Return on Assets (ROA) | -9.32% | -41.0% |
| Return on Invested Capital (ROIC) | -17.9% | -32.2% |
| Return on Capital Employed (ROCE) | -9.97% | -38.0% |
Growth
| Measure | Rockwell Medical | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -21.1% | 6.01% |
| FCF Growth (YoY) | -42.6% | 2.34% |
| Revenue Growth (3Y CAGR) | -1.65% | 2.25% |
| Revenue Growth (5Y CAGR) | 2.17% | 6.42% |
Balance sheet
| Measure | Rockwell Medical | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $24.80M | $62.64M |
| Total Debt | $9.00M | $120.13M |
| Net Cash (Debt) | $15.80M | $15.77M |
| Net Cash Per Share | $3.92 | $0.66 |
| Equity (Book Value) | $35.09M | $48.61M |
| Book Value Per Share | $8.70 | $1.36 |
| Tangible Book Value | $24.79M | $23.01M |
| Working Capital | $25.19M | $75.09M |
Financial position
| Measure | Rockwell Medical | Industry median |
|---|---|---|
| Current Ratio | 3.25 | 3.30 |
| Quick Ratio | 2.96 | 2.39 |
| Debt / Equity | 0.26 | 0.51 |
| Debt / FCF | 5.85 | 5.05 |
| Interest Coverage | -3.99 | -7.12 |
Cash flow (trailing twelve months)
| Measure | Rockwell Medical | Industry median |
|---|---|---|
| Operating Cash Flow | $2.90M | -$12.39M |
| Capital Expenditures | -$1.36M | -$1.07M |
| Free Cash Flow | $1.54M | -$20.34M |
| FCF Per Share | $0.38 | -$0.42 |
Efficiency
| Measure | Rockwell Medical | Industry median |
|---|---|---|
| Asset Turnover | 1.27 | 0.38 |
| Inventory Turnover | 16.37 | 2.67 |
| Revenue Per Employee | $441.97K | $398.96K |
| Profits Per Employee | -$32.38K | -$705.27K |
| Employee Count | 157 | 74 |
Dividends and yields
| Measure | Rockwell Medical | Industry median |
|---|---|---|
| Earnings Yield | -16.8% | -22.8% |
| FCF Yield | 5.10% | -9.02% |
Shares
| Measure | Rockwell Medical | Industry median |
|---|---|---|
| Shares Outstanding | 4,030,470 | 58,139,000 |
| Shares Change (YoY) | 17.0% | 11.1% |
| Shares Change (QoQ) | 0.63% | 0.54% |
| Float | 0 | 49,154,900 |
| Shares Held by Insiders | 100.0% | 11.6% |
| Shares Held by Institutions | 0.54% | 59.4% |
Scores
| Measure | Rockwell Medical | Industry median |
|---|---|---|
| Altman Z-Score | -7.71 | -0.27 |
| Piotroski F-Score | 2 | 4 |
| Beneish M-Score | -2.81 | -2.62 |
Calculated by StockData from Rockwell Medical's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.